Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright
Market Beat·
- HC Wainwright raised its Q3 2026 earnings estimate for Prime Medicine to a loss of $0.28 per share while maintaining a Buy rating and an $8.00 price objective.
- The biotechnology company recently reported Q2 earnings meeting consensus estimates at a loss of $0.24 per share alongside $1.15 million in quarterly revenue.
- Prime Medicine is advancing its pipeline by pushing PM577 into a first-in-human clinical study for Wilson disease while attracting significant recent investments from institutional holders.